Humacyte, Inc. (NASDAQ:HUMA) Receives $13.00 Consensus PT from Analysts

Shares of Humacyte, Inc. (NASDAQ:HUMA) have been assigned an average recommendation of “Buy” from the eight research firms that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $13.71.

Several research firms recently weighed in on HUMA. EF Hutton Acquisition Co. I raised shares of Humacyte to a “strong-buy” rating in a research note on Monday, September 9th. BTIG Research reissued a “buy” rating and issued a $10.00 price target on shares of Humacyte in a report on Friday, October 18th. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective (up previously from $12.00) on shares of Humacyte in a research note on Friday, December 20th. Cantor Fitzgerald reissued an “overweight” rating and issued a $13.00 target price on shares of Humacyte in a research note on Friday, September 20th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $25.00 price target on shares of Humacyte in a research report on Friday, December 20th.

Humacyte Trading Down 3.0 %

NASDAQ:HUMA opened at $4.51 on Thursday. The company has a current ratio of 1.10, a quick ratio of 1.10 and a debt-to-equity ratio of 0.61. Humacyte has a 1-year low of $2.48 and a 1-year high of $9.97. The firm has a market capitalization of $567.62 million, a price-to-earnings ratio of -3.37 and a beta of 1.38. The business’s 50-day moving average price is $4.78 and its two-hundred day moving average price is $5.79.

Insider Activity at Humacyte

In other Humacyte news, CEO Laura E. Niklason sold 811,172 shares of Humacyte stock in a transaction on Monday, November 18th. The shares were sold at an average price of $4.44, for a total value of $3,601,603.68. Following the sale, the chief executive officer now directly owns 2,419,712 shares in the company, valued at approximately $10,743,521.28. The trade was a 25.11 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Brady W. Dougan sold 427,459 shares of the business’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total transaction of $1,855,172.06. Following the sale, the director now directly owns 1,992,253 shares in the company, valued at $8,646,378.02. This trade represents a 17.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,500,000 shares of company stock valued at $6,606,799. 11.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. State Street Corp grew its stake in shares of Humacyte by 66.1% in the third quarter. State Street Corp now owns 4,764,155 shares of the company’s stock valued at $25,917,000 after buying an additional 1,895,529 shares in the last quarter. Millennium Management LLC raised its position in Humacyte by 504.3% during the second quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock worth $7,677,000 after acquiring an additional 1,334,641 shares in the last quarter. Renaissance Technologies LLC grew its position in shares of Humacyte by 693.0% in the 2nd quarter. Renaissance Technologies LLC now owns 600,300 shares of the company’s stock valued at $2,881,000 after acquiring an additional 524,600 shares during the period. Marshall Wace LLP increased its stake in shares of Humacyte by 3,301.5% during the 2nd quarter. Marshall Wace LLP now owns 463,662 shares of the company’s stock worth $2,226,000 after purchasing an additional 450,031 shares during the last quarter. Finally, Deerfield Management Company L.P. Series C acquired a new position in shares of Humacyte during the 2nd quarter worth about $1,550,000. Institutional investors and hedge funds own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.